These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38902191)

  • 41. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings.
    Lee CM; Yoon EL; Kim M; Kang BK; Cho S; Nah EH; Jun DW
    Hepatology; 2024 Jun; 79(6):1393-1400. PubMed ID: 38100294
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study.
    Jeong S; Oh YH; Ahn JC; Choi S; Park SJ; Kim HJ; Lee G; Son JS; Jang H; Lee DH; Sha M; Chen L; Kim W; Park SM
    Clin Mol Hepatol; 2024 Jul; 30(3):487-499. PubMed ID: 38711390
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association between triglyceride-glucose related indices with the all-cause and cause-specific mortality among the population with metabolic syndrome.
    Wei X; Min Y; Song G; Ye X; Liu L
    Cardiovasc Diabetol; 2024 Apr; 23(1):134. PubMed ID: 38658993
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.
    Lee HH; Lee HA; Kim EJ; Kim HY; Kim HC; Ahn SH; Lee H; Kim SU
    Gut; 2024 Feb; 73(3):533-540. PubMed ID: 37907259
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Misclassified Alcohol-related Liver Disease is Common in Presumed Metabolic Dysfunction-associated Steatotic Liver Disease and Highly Increases Risk for Future Cirrhosis.
    Nasr P; Wester A; Ekstedt M; Strandberg R; Kechagias S; Shang Y; Widman L; Hagström H
    Clin Gastroenterol Hepatol; 2024 May; 22(5):1048-1057.e2. PubMed ID: 38237695
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Associations between Healthy Eating Patterns and Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Case-Control Study.
    Huang X; Gan D; Fan Y; Fu Q; He C; Liu W; Li F; Ma L; Wang M; Zhang W
    Nutrients; 2024 Jun; 16(12):. PubMed ID: 38931312
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metabolic dysfunction-associated steatotic liver disease and the risk of mortality in individuals with type 2 diabetes: a systematic review and meta-analysis.
    Wongtrakul W; Charatcharoenwitthaya N; Charatcharoenwitthaya P
    Eur J Gastroenterol Hepatol; 2024 Apr; 36(4):351-358. PubMed ID: 38407898
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study.
    Oh J; Kim BK; Yoon JH; Lee HH; Park H; Lee J; Park Y; Yun B; Chung J
    Cancers (Basel); 2024 Sep; 16(18):. PubMed ID: 39335133
    [No Abstract]   [Full Text] [Related]  

  • 49. Prevalence and prognosis of patients with MASLD-related cirrhosis after an ICU hospitalization in France: A single-centre prospective study.
    Sultanik P; Lherault G; Bouzbib C; Ratziu V; Pais R; Mouri S; Thabut D; Rudler M
    Aliment Pharmacol Ther; 2024 Sep; 60(6):796-810. PubMed ID: 39034817
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study.
    Han E; Lee BW; Kang ES; Cha BS; Ahn SH; Lee YH; Kim SU
    Metabolism; 2024 Mar; 152():155789. PubMed ID: 38224909
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The prevalence and predictors of metabolic dysfunction-associated steatotic liver disease and fibrosis/cirrhosis among adolescents/young adults.
    Perumpail BJ; Manikat R; Wijarnpreecha K; Cholankeril G; Ahmed A; Kim D
    J Pediatr Gastroenterol Nutr; 2024 Jul; 79(1):110-118. PubMed ID: 38623942
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association between the skeletal muscle mass to visceral fat area ratio and metabolic dysfunction-associated fatty liver disease: A cross-sectional study of NHANES 2017-2018.
    Mai Z; Chen Y; Mao H; Wang L
    J Diabetes; 2024 Jun; 16(6):e13569. PubMed ID: 38751375
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population.
    Schneider CV; Schneider KM; Raptis A; Huang H; Trautwein C; Loomba R
    Aliment Pharmacol Ther; 2024 May; 59(10):1271-1281. PubMed ID: 38500443
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association between diet soft drink consumption and metabolic dysfunction-associated steatotic liver disease: findings from the NHANES.
    Wu Y; Tan Z; Zhen J; Liu C; Zhang J; Liao F; Dong W
    BMC Public Health; 2023 Nov; 23(1):2286. PubMed ID: 37985986
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sex and Race-Ethnic Disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease: An Analysis of 40,166 Individuals.
    Fu CE; Teng M; Tung D; Ramadoss V; Ong C; Koh B; Lim WH; Tan DJH; Koh JH; Nah B; Syn N; Tamaki N; Siddiqui MS; Wijarnpreecha K; Ioannou GN; Nakajima A; Noureddin M; Sanyal AJ; Ng CH; Muthiah M
    Dig Dis Sci; 2024 Sep; 69(9):3195-3205. PubMed ID: 38940975
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The prognostic value of metabolic dysfunction-associated steatotic liver disease in acute myocardial infarction: A propensity score-matched analysis.
    Kong G; Cao G; Koh J; Chan SP; Zhang A; Wong E; Chong B; Jauhari SM; Wang JW; Mehta A; Figtree GA; Mamas MA; Ng G; Chan KH; Chai P; Low AF; Lee CH; Yeo TC; Yip J; Foo R; Tan HC; Huang DQ; Muthiah M; Chan MY; Loh PH; Chew NWS
    Diabetes Obes Metab; 2024 Aug; 26(8):3328-3338. PubMed ID: 38779875
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness of 1-year pemafibrate treatment on steatotic liver disease: the influence of alcohol consumption.
    Iwasa M; Sugimoto R; Eguchi A; Tamai Y; Shigefuku R; Fujiwara N; Tanaka H; Kobayashi Y; Ikoma J; Kaito M; Nakagawa H
    Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):793-801. PubMed ID: 38526942
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study.
    Iwaki M; Fujii H; Hayashi H; Toyoda H; Oeda S; Hyogo H; Kawanaka M; Morishita A; Munekage K; Kawata K; Tsutsumi T; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Kamada Y; Takahashi H; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T
    Clin Mol Hepatol; 2024 Apr; 30(2):225-234. PubMed ID: 38263684
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MAFLD identifies patients with significant hepatic fibrosis better than MASLD.
    Pan Z; Al-Busafi SA; Abdulla M; Fouad Y; Sebastiani G; Eslam M
    Hepatol Int; 2024 Jun; 18(3):964-972. PubMed ID: 38717690
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adherence to a healthy lifestyle including sleep and sedentary behaviors and risk of metabolic dysfunction-associated steatotic liver disease in Chinese adults.
    Zhang S; Huo Z; Borné Y; Meng G; Zhang Q; Liu L; Wu H; Gu Y; Sun S; Wang X; Zhou M; Jia Q; Song K; Ma L; Qi L; Niu K
    Prev Med; 2024 Jul; 184():107971. PubMed ID: 38657685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.